Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

COMORBIDITY MECHANISMS OF ANXIETY AND PARKINSON’S DISEASE

Project description

Shared neurotransmitter systems may mediate motor dysfunction and anxiety in Parkinson's

Parkinson's disease (PD) is a neurodegenerative disorder resulting in progressive motor dysfunction related to loss of dopaminergic neurons in the brain. Depression and anxiety are also very common in PD. These conditions may be related to neurochemical changes in dopamine, serotonin and norepinephrine in PD, but more research is needed to confirm this. The EU-funded AND-PD project is taking a closer look at a possible link between degeneration of dopaminergic neurons in PD and co-morbid anxiety. Scientists are exploring whether RNA-based approaches targeting the dopaminergic system can relieve anxiety in PD models. They will supplement these studies with the analysis of patient databases of brain images, looking for correlations of anxiety markers and dopaminergic and serotonergic function.

Objective

AND-PD investigates causative mechanisms of anxiety (with or without depression) as a non-motor co-morbidity of Parkinson’s Disease (PD) and aims to understand the functional and pathological changes in the brainstem resulting from PD. This will provide new insights to advance personalised treatment of PD patients and open new research avenues supporting prevention, diagnosis and management of co-morbidities in PD patients.
Using models of mental comorbidities of PD, AND-PD will investigate functional changes in brainstem nuclei and establish the link with the anxiety phenotype. Findings will be used to inform pre-clinical (rodent, non-human primate and biobank samples) and clinical research (fMRI and PET imaging, behavioural analysis, retrospective cohort analysis) to identify and correlate causalities between dysfunctional neurocircuitry and co-morbid anxiety of PD. To prove causality, AND-PD will i) analyse anxiety in neurotoxin and genetic models of PD; ii) assess the physiological impact and behavioural effects of interventions that selectively reproduce the damage caused by PD in the brainstem; and iii) determine the ability of RNA based approaches to counteract anxiety associated with PD. To demonstrate the link in human patients, AND-PD will analyse patient databases and correlate measures of anxiety with: 1) signs of neuropathology in PD brain samples’ brainstem and 2) clinical and functional biomarkers of dysfunctional neurotransmission through brainstem imaging in patients. AND-PD beneficiaries’ experience in translational research will help ‘bridge the gap’ between preclinical and clinical experiments and help identify new anatomical targets and markers (molecular, functional and pathological,) to support better diagnosis, management and treatment of co-morbidities in PD patients.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

RIA - Research and Innovation action

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-SC1-BHC-2018-2020

See all projects funded under this call

Coordinator

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Net EU contribution
€ 805 027,78
Address
CALLE SERRANO 117
28006 Madrid
Spain
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Links
Total cost
€ 805 027,78

Participants (11)